Product Overview
Cagrilintide is a synthetic amylin analog supplied by PeptaCo for qualified laboratory research. It is designed for studies involving amylin receptor signaling, metabolic regulation, and peptide-receptor pharmacology. Cagrilintide is widely referenced in metabolic research and combination pathway investigations.
Key Product Details
- Product Name: Cagrilintide
- Specification: 5mg per vial
- Product Form: Lyophilized powder
- Category: GLP-1 & Metabolic Research Peptides
- Research Target: Amylin receptor signaling
Chemical Identity
Cagrilintide is a long-acting amylin analog peptide engineered for enhanced stability in research settings. It is structurally related to human amylin and is used as a tool compound for studying amylin receptor biology and metabolic signaling pathways. This listing covers the 5mg specification under catalog number CGL5.
Research Context
Cagrilintide is studied in metabolic research for its interaction with amylin receptor pathways and its role in energy homeostasis investigations. It is commonly referenced in combination studies with incretin-pathway research compounds to explore complementary metabolic signaling mechanisms. PeptaCo supplies Cagrilintide in high-purity format for qualified laboratory customers.
Storage and Handling
Store in a cool, dry place away from direct light. Follow batch-specific storage instructions provided with the certificate of analysis. Avoid repeated freeze-thaw cycles. Handle using standard laboratory practices.
Documentation and Quality
Batch-specific analytical documentation is available to qualified customers upon request. Contact PeptaCo with the product SKU and required quantity to request the current documentation package, which may include identity confirmation, purity analysis, and batch traceability records.
Important Notice
This product is supplied for qualified laboratory research and analytical applications only. It is not for human or veterinary use. Product specifications may vary by batch. Appearance, analytical results, counter-ion information, and other release specifications should be confirmed against the certificate issued for the current batch.
